# US 2013/0252977 A1 · Raf Inhibitor Compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0252977 A1
- Document ID: US20130252977A1
- Status: Published application
- Kind: A1
- Application number: 13/785,575
- Filed: 2013-03-05
- Published: 2013-09-26
- Earliest claimed: 2012-03-07
- Assignees: Deciphera Pharmaceuticals, LLC; Eli Lilly and Company
- Applicants: Deciphera Pharmaceuticals, LLC; Eli Lilly and Company
- Inventors: Matthew Carl Allgeier; Daniel L. Flynn; Michael D. Kaufman; Phenil J. Patel; Craig D. Wolfangel
- Web page: https://patentgrep.com/patent/US20130252977A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 471/12: in which the condensed system contains three hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a pyrido[2,3-d]pyrimidine compound, or a pharmaceutically acceptable salt thereof, that inhibits Raf and, therefore, may be useful in treating cancer.

## Claims

### Claim at position 1

-16. (canceled)

### Claim 17

A compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The compound according to claim 17 which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea.

### Claim 19 (depends on 18)

The compound according to claim 18 which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea in crystalline form characterized by a X-ray powder diffraction pattern having characteristic peaks, in 2θ±0.2, occurring at 16.0 and one or more of 6.9, 7.0, 18.2, and 23.2.

### Claim 20

A pharmaceutical composition comprising a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable carrier.

### Claim 21

A pharmaceutical composition comprising a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

### Claim 22 (depends on 21)

The pharmaceutical composition according to claim 21 comprising the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea.

### Claim 23 (depends on 22)

The pharmaceutical composition according to claim 22 comprising the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea in crystalline form characterized by a X-ray powder diffraction pattern having characteristic peaks, in 2θ±0.2, occurring at 16.0 and one or more of 6.9, 7.0, 18.2, and 23.2.

### Claim 24

A pharmaceutical composition comprising a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea, or a pharmaceutically acceptable salt thereof, and polyvinyl pyrrolidone vinyl acetate (PVP-VA).

### Claim 25 (depends on 24)

The pharmaceutical composition according to claim 24 comprising the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea.

### Claim 26 (depends on 25)

The pharmaceutical composition according to claim 25 comprising the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea in crystalline form characterized by a X-ray powder diffraction pattern having characteristic peaks, in 2θ±0.2, occurring at 16.0 and one or more of 6.9, 7.0, 18.2, and 23.2.

### Claim 27 (depends on 24)

The pharmaceutical composition according to claim 24 wherein the PVP-VA is Kollidon® VA 64.

### Claim 28 (depends on 25)

The pharmaceutical composition according to claim 25 wherein the PVP-VA is Kollidon® VA 64.

### Claim 29 (depends on 26)

The pharmaceutical composition according to claim 26 wherein the PVP-VA is Kollidon® VA 64.

### Claim 30

A method of treating cancer, comprising administering to a patient in need thereof, an effective amount of a compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl) phenyl) urea, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of thyroid cancer, ovarian cancer, melanoma, acute myelogenous leukemia (AML), and colorectal cancer.

### Claim 31 (depends on 30)

The method according to claim 30 comprising the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl) phenyl) urea.

### Claim 32 (depends on 31)

The method according to claim 31 comprising the compound which is 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl) phenyl) urea in crystalline form characterized by a X-ray powder diffraction pattern having characteristic peaks, in 2θ±0.2, occurring at 16.0 and one or more of 6.9, 7.0, 18.2, and 23.2.

### Claim 33 (depends on 30)

The method according to claim 30, wherein the cancer is melanoma.

### Claim 34 (depends on 31)

The method according to claim 31, wherein the cancer is melanoma.

### Claim 35 (depends on 32)

The method according to claim 32, wherein the cancer is melanoma.

### Claim 36 (depends on 30)

The method according to claim 30, wherein the cancer is colorectal cancer.

### Claim 37 (depends on 31)

The method according to claim 31, wherein the cancer is colorectal cancer.

### Claim 38 (depends on 32)

The method according to claim 32, wherein the cancer is colorectal cancer.
